Pancreatic Adeno-MiNEN, a Rare Newly Defined Entity with Challenging Diagnosis and Treatment: A Case Report with Systematic Literature Review and Pooled Analysis.
MiNEN
mixed neuroendocrine-non neuroendocrine neoplasm
pancreatic tumour
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 Aug 2022
26 Aug 2022
Historique:
received:
25
07
2022
revised:
20
08
2022
accepted:
22
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) are a peculiar entity that can occur throughout the whole gastrointestinal trait, and pancreatic localization is rare. Their main characteristic is the presence of at least a neuroendocrine and an epithelial component, each accounting for at least 30% of the tumour mass. The presence of epithelial ductal component defines adeno-MiNEN. We report a case of a 59-year-old woman affected by pancreatic adeno-MiNEN with challenging diagnosis and successfully treated. A systematic literature review and pooled analysis was also performed, aiming to define the management and outcomes of pancreatic adeno-MiNEN. Out of 190 identified records, 15 studies including 28 patients affected by pancreatic-adeno-MiNEN were included in the analysis. Pancreatic adeno-MiNEN occurred mainly in males (82.8%) and at a mean age of 61.7 (range: 24-82) years. Pre-operative diagnosis was possible only in 14.2% of cases. At presentation, the majority had already advanced disease (TNM stage III (53.8%) and stage IV 19.3%). Adjuvant therapy was performed in 55% of patients, and the tumour recurrence rate was in 30% of cases. Median disease-free survival (DFS) was 12 months (range: 0-216 months) with a 5-year DFS of 16.6%, while the median overall survival (OS) was 12 months (range: 0-288 months) with a 5-year OS of 23.5%. Pancreatic adeno-MiNENs are rare; as they have very heterogenous behaviour, they are rarely diagnosed preoperatively and have poor prognosis. Treatment of localised MiNEN still relies on radical surgical resection, which seems essential to achieve a good oncological prognosis. International registry on MiNEN is necessary to improve the knowledge on this rare tumour and to improve its outcomes.
Identifiants
pubmed: 36078951
pii: jcm11175021
doi: 10.3390/jcm11175021
pmc: PMC9457227
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Balkan Med J. 2018 Mar 19;35(3):263-267
pubmed: 29551754
Neuroendocrinology. 2017 Feb 11;105(3):196-200
pubmed: 28190015
Medicine (Baltimore). 2015 Dec;94(48):e2156
pubmed: 26632896
Virchows Arch. 1999 Dec;435(6):606-11
pubmed: 10628803
Cancers (Basel). 2012 Jan 16;4(1):11-30
pubmed: 24213223
Neuroendocrinology. 2017 Feb 25;105(3):255-265
pubmed: 28237989
Pathol Int. 2002 Nov;52(11):740-6
pubmed: 12685552
Neuroendocrinology. 2017;105(4):412-425
pubmed: 28803232
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Cancer. 2014 Sep 15;120(18):2814-23
pubmed: 24771552
J Surg Oncol. 2008 Apr 1;97(5):469-75
pubmed: 18161862
BMJ Case Rep. 2011 Apr 19;2011:
pubmed: 22696627
Histopathology. 2002 Aug;41(2):122-6
pubmed: 12147089
JOP. 2005 Sep 10;6(5):449-54
pubmed: 16186667
Pancreas. 2013 Apr;42(3):429-35
pubmed: 23462323
Virchows Arch. 2021 Jun;478(6):1215-1219
pubmed: 33005981
BMJ Case Rep. 2020 Apr 27;13(4):
pubmed: 32345587
Surg Case Rep. 2016 Dec;2(1):133
pubmed: 27848241
Medicine (Baltimore). 2017 Mar;96(9):e6225
pubmed: 28248881
Expert Rev Anticancer Ther. 2019 Dec;19(12):1029-1050
pubmed: 31738624
Int Surg. 2011 Apr-Jun;96(2):153-8
pubmed: 22026308
Ann Endocrinol (Paris). 2019 Jun;80(3):172-173
pubmed: 31064662
Endocr Pathol. 2016 Dec;27(4):284-311
pubmed: 27169712
Pancreatology. 2021 Jan;21(1):224-235
pubmed: 33309225
Med Mol Morphol. 2011 Mar;44(1):58-62
pubmed: 21424939